Fiche centre
Austin Hospital
Heidelberg — Australia
Essais liés10clinical trials
VilleHeidelberglocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04544436
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Soticlestat | Épilepsie | Phase 2 | NCT03635073 | Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06660394 | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06719141 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | ACTIVE_NOT_RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06908226 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | ENROLLING_BY_INVITATION |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Diroximel Fumarate | SEP | À vérifier | NCT05658497 | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |